DNAprint Genomics (DNAG)

[easymedicine]

important reading from recent K..........

All of these paragraphs can be found in the last K released by DNAP http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094

We also face serious competition from competitors in the forensic DNA testing
market, consumer DNA products market and the contract services outsourcing
market which we are also a participant. Accordingly, we may be unable to compete
successfully with our competitors in said markets to generate revenue
significant to sustain our operations.

We may never become profitable and continue as a going concern because we have
had losses since our inception which may negatively impact our ability to
achieve our business objectives. We may never be able to reduce these losses,
which will require us to seek additional debt or equity financing that may not
be available to us.

Our independent auditors have expressed doubt about our ability to continue as a
going concern, which may hinder our ability to obtain future financing.

We may need immediate funds and may not be able to obtain any additional
financing in the amounts or at the times that we may require the financing or,
if we do obtain any financing, that it would be on acceptable terms.
Accordingly, we may have to curtail our business if we cannot find adequate
funding.

We currently have no legally binding commitments with any third parties to
obtain any material amount of additional equity or debt financing. However,
management intends to continue its relationship with La Jolla Cove Investors,
Inc. and it will continue under its agreement to receive funding totaling $8
million. As of December 31, 2004, La Jolla Cove Investors, Inc. (LJCI) converted
$310,000 of convertible debenture into our common stock and exercised
non-detachable warrants to purchase 4,650,000 shares of our common stock. The
combined transactions resulted in us receiving cash of $4,752,169 net of
$397,831 of cash stock issuance costs. We also received $255,000 prepayment for
future warrant exercises. It is anticipated that the minimum conversions of the
outstanding debenture into common stock and the related exercise of the
non-detachable warrants will fund our operating activities through 2004 and that
together with the additional funding anticipated to be received from Dutchess,
our operations will be funded through 2006.

Despite the LJCI financing, we may need immediate funds and may not be
able to obtain any additional financing in the amounts or at the times that we
may require the financing or, if we do obtain any financing, that it would be on
acceptable terms because of the following:

- we have no assets to pledge as security for the loan

- we are in poor financial condition

- we may be viewed as a high market risk

Our failure to obtain sufficient additional financing could result in the
delay or abandonment of some or all of our development, expansion and
expenditures, which could harm our business and the value of our common stock.